Chemed (CHE)
(Delayed Data from NYSE)
$577.77 USD
-3.78 (-0.65%)
Updated Oct 7, 2024 04:00 PM ET
After-Market: $578.68 +0.91 (0.16%) 7:58 PM ET
3-Hold of 5 3
C Value A Growth B Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$577.77 USD
-3.78 (-0.65%)
Updated Oct 7, 2024 04:00 PM ET
After-Market: $578.68 +0.91 (0.16%) 7:58 PM ET
3-Hold of 5 3
C Value A Growth B Momentum B VGM
Zacks News
AMED or CHE: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
AMED vs. CHE: Which Stock Is the Better Value Option?
Why Chemed (CHE) is a Top Growth Stock for the Long-Term
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Should iShares MSCI USA Small-Cap Min Vol Factor ETF (SMMV) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for SMMV
Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Chemed (CHE) Up 5.7% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Chemed (CHE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Here's Why Chemed (CHE) is a Strong Growth Stock
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
ADUS vs. CHE: Which Stock Is the Better Value Option?
by Zacks Equity Research
ADUS vs. CHE: Which Stock Is the Better Value Option?
Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Why Chemed (CHE) is a Top Growth Stock for the Long-Term
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
3 Reasons Why Growth Investors Shouldn't Overlook Chemed (CHE)
by Zacks Equity Research
Chemed (CHE) possesses solid growth attributes, which could help it handily outperform the market.
Chemed (CHE) Q2 Earnings Miss Estimates, Margins Expand
by Zacks Equity Research
Chemed's (CHE) VITAS segment delivers impressive revenue growth and margin expansion in the second quarter of 2024.
Chemed (CHE) Misses Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Chemed (CHE) delivered earnings and revenue surprises of -1.26% and 1.17%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Should You Keep Chemed (CHE) Stock in Your Portfolio Now?
by Zacks Equity Research
Chemed's (CHE) robust VITAS business and strong financial stability raise investors' optimism.
Chemed (CHE) Down 3.1% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Chemed (CHE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Should iShares MSCI USA Small-Cap Min Vol Factor ETF (SMMV) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for SMMV
EHC or CHE: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
EHC vs. CHE: Which Stock Is the Better Value Option?
Chemed (CHE) Lags Q1 Earnings Estimates, Reaffirms 2024 View
by Zacks Equity Research
Chemed's (CHE) first-quarter 2024 results reflect VITAS' impressive revenue growth and improved average revenues per patient per day.
Chemed (CHE) Q1 Earnings Miss Estimates
by Zacks Equity Research
Chemed (CHE) delivered earnings and revenue surprises of -4.94% and 0.35%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Here's Why You Should Retain Chemed (CHE) Stock for Now
by Zacks Equity Research
Investors are optimistic about Chemed (CHE), backed by the strong performance of the VITAS Healthcare and Roto-Rooter segments.
Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Chemed (CHE) Up 2.5% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Chemed (CHE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Chemed (CHE) Reaches a New 52-Week High: What's Driving It?
by Zacks Equity Research
Investors are optimistic about Chemed (CHE) on strong performance across the VITAS and Roto-Rooter segments.
Chemed's (CHE) VITAS Segment Inks New Deal With Covenant Care
by Zacks Equity Research
Chemed's (CHE) VITAS segment is set to acquire the hospice assets of Covenant Care in Florida and Alabama.
Centene (CNC), Pearl Health Unite to Enhance Value-Based Care
by Zacks Equity Research
Centene (CNC) collaborates with Pearl Health to enhance value-based care services for Medicare Advantage members.